Imetelstat + Ruxolitinib

About Geron

Geron Corporation is a commercial-stage biopharmaceutical company with a mission to extend and enhance the lives of patients with blood cancers by changing the course of disease through targeted telomerase inhibition. The company achieved a historic milestone with the June 2024 FDA approval of its first-in-class telomerase inhibitor, imetelstat (Rytelo™), for transfusion-dependent anemia in lower-risk myelodysplastic syndromes (MDS). Geron's strategy is to leverage its proprietary platform to expand imetelstat's label into other myeloid malignancies, including myelofibrosis (MF) and acute myeloid leukemia (AML), aiming to build a leading franchise in hematologic oncology.

Therapeutic Areas